A Case Report of SAPHO Syndrome Treated with Oral Alendronate.
10.4078/jrd.2015.22.5.313
- Author:
Hyun Ik SHIM
1
;
Won PARK
;
Yeo Ju KIM
;
Kyong Hee JUNG
;
Ji Hyeon BAEK
;
Mie Jin LIM
;
Kowoon JOO
;
Seong Ryul KWON
Author Information
1. Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Korea. rhksr@inha.ac.kr
- Publication Type:Case Report
- Keywords:
Acquired hyperostosis syndrome;
Therapeutics;
Alendronate
- MeSH:
Acne Vulgaris;
Acquired Hyperostosis Syndrome*;
Alendronate*;
Antirheumatic Agents;
Delayed Diagnosis;
Diagnosis;
Fingers;
Humans;
Hyperostosis;
Injections, Intravenous;
Osteitis;
Spondylarthropathies;
Synovitis;
Tumor Necrosis Factor-alpha
- From:Journal of Rheumatic Diseases
2015;22(5):313-316
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
SAPHO syndrome, characterized by synovitis, acne, pustulosis, hyperostosis, and osteitis is rare compared to other spondyloarthropathies. It is also difficult to diagnose, and treatment methods have not yet been fully identified. Approximately 72% of patients are diagnosed with at least one other disease before a final diagnosis of SAPHO syndrome. In addition, SAPHO syndrome is subject to a delayed diagnosis period of 4.5 to 9.1 years. Medications such as non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, and tumor necrosis factor inhibitors are used in treatment of SAPHO syndrome. Bisphosphonate is also used for refractory SAPHO syndrome; however, most reports on this relate to intravenous injection of medication. The authors experienced and subsequently reported on a case involving a patient with SAPHO syndrome accompanied by fracture and infection of the left second finger who was treated with the oral biphosphonate, alendronate.
